{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:29:52Z","timestamp":1773296992058,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,12,22]],"date-time":"2007-12-22T00:00:00Z","timestamp":1198281600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s00259-007-0659-z","type":"journal-article","created":{"date-parts":[[2007,12,21]],"date-time":"2007-12-21T10:04:50Z","timestamp":1198231490000},"page":"756-765","source":"Crossref","is-referenced-by-count":49,"title":["Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases"],"prefix":"10.1007","volume":"35","author":[{"given":"Marnix G. E. H.","family":"Lam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amel","family":"Dahmane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wil H. M.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"van Rijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M. H.","family":"de Klerk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard A.","family":"Zonnenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,12,22]]},"reference":[{"issue":"3","key":"659_CR1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000474185","volume":"30","author":"GA Dijkman","year":"1996","unstructured":"Dijkman GA, Debruyne FM. Epidemiology of prostate cancer. Eur Urol 1996;30(3):281-95.","journal-title":"Eur Urol"},{"issue":"1","key":"659_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1634\/theoncologist.5-1-36","volume":"5","author":"G Auclerc","year":"2000","unstructured":"Auclerc G, Antoine EC, Cajfinger F, Brunet-Pommeyrol A, Agazia C, Khayat D. Management of advanced prostate cancer. Oncologist 2000;5(1):36-44.","journal-title":"Oncologist"},{"issue":"1","key":"659_CR3","first-page":"63","volume":"35","author":"JE Bayouth","year":"1994","unstructured":"Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 1994;35(1):63-9.","journal-title":"J Nucl Med"},{"issue":"4","key":"659_CR4","first-page":"495","volume":"28","author":"WF Goeckeler","year":"1987","unstructured":"Goeckeler WF, Edwards B, Volkert WA, Holmes RA, Simon J, Wilson D. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 1987;28(4):495-504.","journal-title":"J Nucl Med"},{"issue":"6","key":"659_CR5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/107327489800500604","volume":"5","author":"R Rago","year":"1998","unstructured":"Rago R. Management of hormone-sensitive and hormone-refractory metastatic prostate cancer. Cancer Control 1998;5(6):513-21.","journal-title":"Cancer Control"},{"issue":"7","key":"659_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00259-006-0343-8","volume":"34","author":"S Ricci","year":"2007","unstructured":"Ricci S, Boni G, Pastina I, Genovesi D, Cianci C, Chiacchio S, et al. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2007;34(7):1023-30.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"19","key":"659_CR7","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458-68.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"659_CR8","first-page":"3180","volume":"13","author":"S Berry","year":"2006","unstructured":"Berry S, Waldron T, Winquist E, Lukka H. The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials. Can J Urol 2006;13(4):3180-8.","journal-title":"Can J Urol"},{"issue":"1","key":"659_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.bone.2005.12.004","volume":"39","author":"G Storto","year":"2006","unstructured":"Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, et al. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 2006;39(1):35-41.","journal-title":"Bone"},{"issue":"5","key":"659_CR10","first-page":"748","volume":"33","author":"SH Hommeyer","year":"1992","unstructured":"Hommeyer SH, Varney DM, Eary JF. Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy. J Nucl Med 1992;33(5):748-50.","journal-title":"J Nucl Med"},{"issue":"4","key":"659_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/00003072-198804000-00008","volume":"13","author":"AZ Krasnow","year":"1988","unstructured":"Krasnow AZ, Collier BD, Isitman AT, Hellman RS, Ewey D. False-negative bone imaging due to etidronate disodium therapy. Clin Nucl Med 1988;13(4):264-7.","journal-title":"Clin Nucl Med"},{"issue":"9","key":"659_CR12","first-page":"1782","volume":"32","author":"ED Sandler","year":"1991","unstructured":"Sandler ED, Parisi MT, Hattner RS. Duration of etidronate effect demonstrated by serial bone scintigraphy. J Nucl Med 1991;32(9):1782-4.","journal-title":"J Nucl Med"},{"issue":"9","key":"659_CR13","first-page":"1359","volume":"42","author":"JA Carrasquillo","year":"2001","unstructured":"Carrasquillo JA, Whatley M, Dyer V, Figg WD, Dahut W. Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning. J Nucl Med 2001;42(9):1359-63.","journal-title":"J Nucl Med"},{"issue":"6","key":"659_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/00003072-200206000-00008","volume":"27","author":"CS Marcus","year":"2002","unstructured":"Marcus CS, Saeed S, Mlikotic A, Mishkin F, Pham HL, Javellana T, et al. Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP. Clin Nucl Med 2002;27(6):427-30.","journal-title":"Clin Nucl Med"},{"issue":"7","key":"659_CR15","first-page":"1039","volume":"34","author":"M Pecherstorfer","year":"1993","unstructured":"Pecherstorfer M, Schilling T, Janisch S, Woloszczuk W, Baumgartner G, Ziegler R, et al. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med 1993;34(7):1039-44.","journal-title":"J Nucl Med"},{"issue":"1","key":"659_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s002590050351","volume":"26","author":"JH Tian","year":"1999","unstructured":"Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 1999;26(1):2-7.","journal-title":"Eur J Nucl Med"},{"issue":"15","key":"659_CR17","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1200\/JCO.2003.12.060","volume":"21","author":"H Palmedo","year":"2003","unstructured":"Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003;21(15):2869-75.","journal-title":"J Clin Oncol"},{"issue":"11","key":"659_CR18","first-page":"1814","volume":"30","author":"A Singh","year":"1989","unstructured":"Singh A, Holmes RA, Farhangi M, Volkert WA, Williams A, Stringham LM, et al. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med 1989;30(11):1814-8.","journal-title":"J Nucl Med"},{"issue":"8","key":"659_CR19","first-page":"1451","volume":"33","author":"M Farhanghi","year":"1992","unstructured":"Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992;33(8):1451-8.","journal-title":"J Nucl Med"},{"issue":"6","key":"659_CR20","first-page":"895","volume":"42","author":"AN Serafini","year":"2001","unstructured":"Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001;42(6):895-906.","journal-title":"J Nucl Med"},{"issue":"7","key":"659_CR21","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00259-006-0302-4","volume":"34","author":"L Strigari","year":"2007","unstructured":"Strigari L, Sciuto R, D'Andrea M, Pasqualoni R, Benassi M, Maini CL. Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation. Eur J Nucl Med Mol Imaging 2007;34(7):1031-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"659_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/cncr.22431","volume":"109","author":"O Sartor","year":"2007","unstructured":"Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 2007;109(3):637-43.","journal-title":"Cancer"},{"issue":"4","key":"659_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0221-8747(84)90024-9","volume":"5","author":"ML Smith","year":"1984","unstructured":"Smith ML, Fogelman I, Ralston S, Boyce BF, Boyle IT. Correlation of skeletal uptake of 99mTc-diphosphonate and alkaline phosphatase before and after oral diphosphonate therapy in Paget\u2019s disease. Metab Bone Dis Relat Res 1984;5(4):167-70.","journal-title":"Metab Bone Dis Relat Res"},{"issue":"4","key":"659_CR24","first-page":"705","volume":"36","author":"H Koyano","year":"1995","unstructured":"Koyano H, Schimizu T, Shishiba Y. The bisphosphonate dilemma. J Nucl Med 1995;36(4):705-6.","journal-title":"J Nucl Med"},{"issue":"8","key":"659_CR25","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/00003072-199208000-00011","volume":"17","author":"RD Low","year":"1992","unstructured":"Low RD, Hicks RJ, Arkles LB, Gill G, Adam W. Progressive soft tissue uptake of Tc-99m MDP reflecting metastatic microcalcification. Clin Nucl Med 1992;17(8):658-2.","journal-title":"Clin Nucl Med"},{"issue":"12","key":"659_CR26","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1097\/00003072-198812000-00004","volume":"13","author":"BA Eagel","year":"1988","unstructured":"Eagel BA, Stier SA, Wakem C. Non-osseous bone scan abnormalities in multiple myeloma associated with hypercalcemia. Clin Nucl Med 1988;13(12):869-73.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"659_CR27","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1054\/bjoc.1999.1012","volume":"82","author":"P Garnero","year":"2000","unstructured":"Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000;82(4):858-64.","journal-title":"Br J Cancer"},{"issue":"3","key":"659_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/ctrv.2000.0213","volume":"27","author":"P Garnero","year":"2001","unstructured":"Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev 2001;27(3):187-92.","journal-title":"Cancer Treat Rev"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-007-0659-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-007-0659-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-007-0659-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-007-0659-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T05:05:45Z","timestamp":1557119145000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-007-0659-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,22]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["659"],"URL":"https:\/\/doi.org\/10.1007\/s00259-007-0659-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,22]]}}}